

In another aspect, there is provided a pharmaceutical composition comprising, as active principle, one or more compounds as disclosed herein, or a pharmaceutically acceptable salt thereof, and at least one therapeutically inert excipient.

5 In another embodiment, there is provided the use of a pharmaceutical composition as defined above in the manufacture of a medicament for the prevention or treatment of mental health diseases or disorders relating to orexinergic dysfunctions.

In another aspect, there is provided a compound as disclosed herein, or a pharmaceutically acceptable salt thereof, for use as a medicament.

10 In another aspect, there is provided the use of a compound as defined herein, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the prevention or treatment of a diseases or disorders relating to orexinergic dysfunctions, selected from sleep disorders, a sleep disorder selected from an insomnia; a primary insomnia; an idiopathic insomnia; an insomnia associated with depression, emotional/mood disorders, aging, Alzheimer's disease or cognitive impairment; REM sleep interruptions; a
 15 breathing-related sleep disorder; a sleep apnea; a periodic limb movement disorder, a restless leg syndrome; a circadian rhythm sleep disorder; a shift work sleep disorder; and a jet-lag syndrome; and an anxiety disorders, selected from a post-traumatic stress disorder, an obsessive compulsive disorder, a panic attack, a phobic anxiety, and an avoidance.
addiction disorders, cognitive dysfunctions, mood disorders, and appetite disorders.

20 In this patent application, a dotted line shows the point of attachment of the radical drawn. For example, the radical drawn below

12. Use of a compound as defined in any one of claims 1 to 9, or of a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the prevention or treatment of a diseases or disorders relating to orexinergic dysfunctions, selected from sleep disorders
 5 a sleep disorder selected from an insomnia; a primary insomnia; an idiopathic insomnia; an insomnia associated with depression, emotional/mood disorders, aging, Alzheimer's disease or cognitive impairment; REM sleep interruptions; a breathing-related sleep disorder; a sleep apnea; a periodic limb movement disorder, a restless leg syndrome; a circadian rhythm sleep disorder; a shift work sleep disorder; and a jet-lag syndrome; and an,
 10 anxiety disorders, selected from a post-traumatic stress disorder, an obsessive compulsive disorder, a panic attack, a phobic anxiety, and an avoidance~~addiction disorders, cognitive dysfunctions, mood disorders, or appetite disorders.~~

13. ~~The use~~ Use of a compound as defined in any one of claims 1 to 9, or of a pharmaceutically acceptable salt thereof, according to claim 12, wherein said diseases or disorders relating to orexinergic dysfunctions is an insomnia; a primary insomnia; an idiopathic insomnia; or an insomnia associated with depression, emotional/mood disorders, aging, Alzheimer's disease or cognitive impairment,
 15 are selected from sleep disorders selected from insomnias; or anxiety disorders selected from post-traumatic stress disorders, obsessive compulsive disorders, panic attacks, phobic anxieties, or avoidance.
 20